Tellurium/Vanadate Doped Hydroxyapatite Nano-Scaffold Carrier for Doxorubicin Colon Cancer Targeting | ||
| Egyptian Journal of Chemistry | ||
| Volume 66, Issue 10, October 2023, Pages 521-528 PDF (1.33 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejchem.2023.189848.7518 | ||
| Authors | ||
| Mayssa Abdel Hady* 1; Mohamed K Ahmed2 | ||
| 1Pharmaceutical Technology Department, National Research Centre, Giza, Egypt. | ||
| 2bDepartment of Physics, Faculty of Science, Suez University, Suez 43518, Egypt | ||
| Abstract | ||
| Designing specific chemotherapy delivery systems that target cancer cells is widely studied nowadays. Different substitutions of tellurium (Te)/vanadate (V) doped hydroxyapatite (HAP) have been suggested to be used as a carrier scaffold for doxorubicin (DOX). In contrast, the ultimated scaffold is coated with chitosan (CS) to be utilized and studied as a colon cancer therapy. Evaluation of DOX release explains the specific cleavage of DOX from CS-coated HAP at enteric pH in a controlled-release state. This formulation was studied with XRD and XPS to confirm composition elements and purity. As displayed from SEM micrographs, it can be illustrated that the morphological alterations and grain size of an average diameter of 0.5-2 µm for 1Te/V-HAP/DOX-CS. Further, it was observed that DOX shows a loading capacity of 99% for all the compositions. The cytotoxicity assay was assessed against HT-29 colorectal cell lines, implying that the activity of DOX loaded nanocomposite was maintained. Therefore, the present investigation recommended that the CS-coated Te/V-HAP/DOX is an excellent nominee for colon cancer treatment. | ||
| Keywords | ||
| Hydroxyapatite; Doxorubicin; Colon cancer; Drug delivery | ||
|
Statistics Article View: 242 PDF Download: 176 |
||
